Galmed Pharmaceuticals (NASDAQ:GLMD) was downgraded by analysts at Maxim Group from a “buy” rating to a “hold” rating in a research report issued on Wednesday, The Fly reports.
GLMD has been the subject of several other research reports. Roth Capital began coverage on shares of Galmed Pharmaceuticals in a research report on Wednesday, November 15th. They set a “buy” rating and a $32.00 price target for the company. ValuEngine lowered shares of Galmed Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, December 1st. Zacks Investment Research lowered shares of Galmed Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, January 11th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $18.00 price target on shares of Galmed Pharmaceuticals in a research report on Friday, October 27th. Three analysts have rated the stock with a hold rating and three have given a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $20.40.
Galmed Pharmaceuticals (GLMD) opened at $9.46 on Wednesday. Galmed Pharmaceuticals has a 52-week low of $3.53 and a 52-week high of $12.22. The firm has a market capitalization of $124.41, a PE ratio of -8.52 and a beta of 2.42.
Galmed Pharmaceuticals Company Profile
Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol.
Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.